Reduced Cytokine Release in Ex Vivo Response to Cilengitide and Cetuximab Is a Marker for Improved Survival of Head and Neck Cancer Patients

Targeting of α(V)β3 and α(V)β5 integrins by cilengitide may reduce growth of solid tumors including head and neck squamous cell carcinoma (HNSCC). Preclinical investigations suggest increased activity of cilengitide in combination with other treatment modalities. The only published trial in HNSCC (A...

Descripción completa

Detalles Bibliográficos
Autores principales: Cedra, Susan, Wiegand, Susanne, Kolb, Marlen, Dietz, Andreas, Wichmann, Gunnar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5615332/
https://www.ncbi.nlm.nih.gov/pubmed/28872582
http://dx.doi.org/10.3390/cancers9090117

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5615332/
https://www.ncbi.nlm.nih.gov/pubmed/28872582
http://dx.doi.org/10.3390/cancers9090117

Ejemplares similares